|
1
|
Palmero EI, Alemar B, Schüler-Faccini L,
Hainaut P, Moreira-Filho CA, Ewald IP, Santos PK, Ribeiro PL,
Oliveira CB, Calvez-Kelm FL, et al: Screening for germline BRCA1,
BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary
breast cancer identified in a population-based study from Southern
Brazil. Genet Mol Biol. 39:210–222. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ford D, Easton DF, Stratton M, Narod S,
Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J,
et al: Genetic heterogeneity and penetrance analysis of the BRCA1
and BRCA2 genes in breast cancer families. The breast cancer
linkage consortium. Am J Hum Genet. 62:676–689. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hall JM, Lee MK, Newman B, Morrow JE,
Anderson LA, Huey B and King MC: Linkage of early-onset familial
breast cancer to chromosome 17q21. Science. 250:1684–1689. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wooster R, Neuhausen SL, Mangion J, Quirk
Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, et al:
Localization of a breast cancer susceptibility gene, BRCA2, to
chromosome 13q12-13. Science. 265:2088–2090. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miki Y, Swensen J, Shattuck-Eidens D,
Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM,
Ding W, et al: A strong candidate for the breast and ovarian cancer
susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ozcelik H, Shi X, Chang MC, Tram E,
Vlasschaert M, Di Nicola N, Kiselova A, Yee D, Goldman A, Dowar M,
et al: Long-range PCR and next-generation sequencing of BRCA1 and
BRCA2 in breast cancer. J Mol Diagn. 14:467–475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chin EL, da Silva C and Hegde M:
Assessment of clinical analytical sensitivity and specificity of
next-generation sequencing for detection of simple and complex
mutations. BMC Genet. 14:62013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Veronesi A, de Giacomi C, Magri MD,
Lombardi D, Zanetti M, Scuderi C, Dolcetti R, Viel A, Crivellari D,
Bidoli E and Boiocchi M: Familial breast cancer: Characteristics
and outcome of BRCA 1–2 positive and negative cases. BMC Cancer.
5:702005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Musolino A, Bella MA, Bortesi B, Michiara
M, Naldi N, Zanelli P, Capelletti M, Pezzuolo D, Camisa R, Savi M,
et al: BRCA mutations, molecular markers, and clinical variables in
early-onset breast cancer: A population-based study. Breast.
16:280–292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tung N, Miron A, Schnitt SJ, Gautam S,
Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim JY, Szász AM, et al:
Prevalence and predictors of loss of wild type BRCA1 in estrogen
receptor positive and negative BRCA1-associated breast cancers.
Breast Cancer Res. 12:R952010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Atchley DP, Albarracin CT, Lopez A, Valero
V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN and Arun BK: Clinical
and pathologic characteristics of patients with BRCA-positive and
BRCA-negative breast cancer. J Clin Oncol. 26:4282–4288. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rebbeck TR, Mitra N, Wan F, Sinilnikova
OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF,
Antoniou AC, et al: Association of type and location of BRCA1 and
BRCA2 mutations with risk of breast and ovarian cancer. JAMA.
313:1347–1361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shiovitz S and Korde LA: Genetics of
breast cancer: A topic in evolution. Ann Oncol. 26:1291–1299.
2015.PubMed/NCBI
|
|
14
|
Trainer AH, Thompson E and James PA: BRCA
and beyond: A genome-first approach to familial breast cancer risk
assessment. Discov Med. 12:433–443. 2011.PubMed/NCBI
|
|
15
|
Paul A and Paul S: The breast cancer
susceptibility genes (BRCA) in breast and ovarian cancers. Front
Biosci (Landmark Ed). 19:605–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sugano K, Nakamura S, Ando J, Takayama S,
Kamata H, Sekiguchi I, Ubukata M, Kodama T, Arai M, Kasumi F, et
al: Cross-sectional analysis of germline BRCA1 and BRCA2 mutations
in Japanese patients suspected to have hereditary breast/ovarian
cancer. Cancer Sci. 99:1967–1976. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim H, Cho DY, Choi DH, Choi SY, Shin I,
Park W, Huh SJ, Han SH, Lee MH, Ahn SH, et al: Characteristics and
spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with
breast and ovarian cancer. Breast Cancer Res Treat. 134:1315–1326.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim YC, Zhao L, Zhang H, Huang Y, Cui J,
Xiao F, Downs B and Wang SM: Prevalence and spectrum of BRCA
germline variants in mainland Chinese familial breast and ovarian
cancer patients. Oncotarget. 7:9600–9612. 2016.PubMed/NCBI
|
|
19
|
Zhang J, Sun J, Chen J, Yao L, Ouyang T,
Li J, Wang T, Fan Z, Fan T, Lin B and Xie Y: Comprehensive analysis
of BRCA1 and BRCA2 germline mutations in a large cohort of 5931
Chinese women with breast cancer. Breast Cancer Res Treat.
158:455–462. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lang GT, Shi JX, Hu X, Zhang CH, Shan L,
Song CG, Zhuang ZG, Cao AY, Ling H, Yu KD, et al: The spectrum of
BRCA mutations and characteristics of BRCA-associated breast
cancers in china: Screening of 2,991 patients and 1,043 controls by
next-generation sequencing. Int J Cancer. 141:129–142. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Blazer KR, Slavin T and Weitzel JN:
Increased reach of genetic cancer risk assessment as a tool for
precision management of hereditary breast cancer. JAMA Oncol.
2:723–724. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cao WM, Gao Y, Yang HJ, Xie SN, Ding XW,
Pan ZW, Ye WW and Wang XJ: Novel germline mutations and
unclassified variants of BRCA1 and BRCA2 genes in Chinese women
with familial breast/ovarian cancer. BMC Cancer. 16:642016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Spearman AD, Sweet K, Zhou XP, McLennan J,
Couch FJ and Toland AE: Clinically applicable models to
characterize BRCA1 and BRCA2 variants of uncertain significance. J
Clin Oncol. 26:5393–5400. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kurian AW, Hare EE, Mills MA, Kingham KE,
McPherson L, Whittemore AS, McGuire V, Ladabaum U, Kobayashi Y,
Lincoln SE, et al: Clinical evaluation of a multiple-gene
sequencing panel for hereditary cancer risk assessment. J Clin
Oncol. 32:2001–2009. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Antoniou A, Pharoah PD, Narod S, Risch HA,
Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et
al: Average risks of breast and ovarian cancer associated with
BRCA1 or BRCA2 mutations detected in case series unselected for
family history: A combined analysis of 22 studies. Am J Hum Genet.
72:1117–1130. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
King MC, Marks JH and Mandell JB; New York
Breast Cancer Study Group, : Breast and ovarian cancer risks due to
inherited mutations in BRCA1 and BRCA2. Science. 302:643–646. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Paluch-Shimon S, Cardoso F, Sessa C,
Balmana J, Cardoso MJ, Gilbert F and Senkus E; ESMO Guidelines
Committee, : Prevention and screening in BRCA mutation carriers and
other breast/ovarian hereditary cancer syndromes: ESMO clinical
practice guidelines for cancer prevention and screening. Ann Oncol.
27 Suppl 5:v103–v110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fan S, Ma YX, Wang C, Yuan RQ, Meng Q,
Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, et al: Role of
direct interaction in BRCA1 inhibition of estrogen receptor
activity. Oncogene. 20:77–87. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lakhani SR, Reis-Filho JS, Fulford L,
Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J,
Rivas C, Bignon YJ, et al: Prediction of BRCA1 status in patients
with breast cancer using estrogen receptor and basal phenotype.
Clin Cancer Res. 11:5175–5180. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sanford RA, Song J, Gutierrez-Barrera AM,
Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero
V and Arun B: High incidence of germline BRCA mutation in patients
with ER low-positive/PR low-positive/HER-2 neu negative tumors.
Cancer. 121:3422–3427. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
van der Groep P, van der Wall E and van
Diest PJ: Pathology of hereditary breast cancer. Cell Oncol
(Dordr). 34:71–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mavaddat N, Barrowdale D, Andrulis IL,
Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M,
Sherman M, et al: Pathology of breast and ovarian cancers among
BRCA1 and BRCA2 mutation carriers: Results from the consortium of
investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol
Biomarkers Prev. 21:134–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Keeney MG, Couch FJ, Visscher DW and
Lindor NM: Non-BRCA familial breast cancer: Review of reported
pathology and molecular findings. Pathology. 49:363–370. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nahleh Z, Otoukesh S, Dwivedi AK,
Mallawaarachchi I, Sanchez L, Saldivar JS, Cataneda K and Heydarian
R: Clinical and pathological characteristics of hispanic
BRCA-associated breast cancers in the American-Mexican border city
of El Paso, TX. Am J Cancer Res. 5:466–471. 2014.PubMed/NCBI
|
|
35
|
Zhang J, Pei R, Pang Z, Ouyang T, Li J,
Wang T, Fan Z, Fan T, Lin B and Xie Y: Prevalence and
characterization of BRCA1 and BRCA2 germline mutations in Chinese
women with familial breast cancer. Breast Cancer Res Treat.
132:421–428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kwong A, Wong LP, Wong HN, Law FB, Ng EK,
Tang YH, Chan WK, Suen DT, Choi C, Ho LS, et al: Clinical and
pathological characteristics of Chinese patients with BRCA related
breast cancer. Hugo J. 3:63–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen W, Pan K, Ouyang T, Li J, Wang T, Fan
Z, Fan T, Lin B, Lu Y, You W and Xie Y: BRCA1 germline mutations
and tumor characteristics in Chinese women with familial or
early-onset breast cancer. Breast Cancer Res Treat. 117:55–60.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gelmon KA, Tischkowitz M, Mackay H,
Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M,
Gilks B, et al: Olaparib in patients with recurrent high-grade
serous or poorly differentiated ovarian carcinoma or
triple-negative breast cancer: A phase 2, multicentre, open-label,
non-randomised study. Lancet Oncol. 12:852–861. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Arun B, Bayraktar S, Liu DD, Gutierrez
Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V,
Meric-Bernstam F, Hortobagyi GN and Albarracin C: Response to
neoadjuvant systemic therapy for breast cancer in BRCA mutation
carriers and noncarriers: A single-institution experience. J Clin
Oncol. 29:3739–3746. 2011. View Article : Google Scholar : PubMed/NCBI
|
